Corey Nobile

*

📍 United States🔄 Updated September 2026💼 12 investments📅 7 years investing🗓 Last invested Feb 2025
VC🌍 United States
12
Total investments
5
Early stage
1
Mid stage
1
Late stage
7y
Years active

Portfolio

12 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Observer
Feb 2025
Standard Nuclear
Board Member
Oct 2024
The mission of Sampling Human is to couple health related decisions to their effects at the single cell level. It is inspired by the founders’ academic and professional efforts to extend what is measurable and to derive what must be measured. The human body is a complex system that cannot be quantified exhaustively or heuristically. Clinical diagnosis today is an imprecise art. On average, diagnosis of rare diseases is 5 years delayed with 50% of delays impacting the outcome. Misdiagnosis is far too common with a 66% likelihood of disagreement between experts. We are stuck with symptoms based medicine. The nature of physiological data is to blame. Decisions today are based on fuzzy variables (tired, drowsy, weak, tingling, itchy, etc). Better decisions will require precise knowledge regarding the fundamental physiological units of our bodies, CELLS.
Board Member
Jan 2024
We sequence proteins. Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. While DNA can reveal biological insights, proteins actually tell us what our bodies will do. We are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biology and disease.
Board Observer
Mar 2023
We create novel optical/photonic components made uniquely possible by our 3D nano fabrication platform to create solutions for sensing, imaging, telecommunications, computation, and display.
Pre-Seed Investor
Jan 2023
Atomic Semi is building a small, fast semiconductor fab. We’ll build the tools ourselves then quickly push them to more advanced geometries. We’re building a small team of exceptional, hands-on engineers to make this happen.
Seed Investor
Apr 2022
Biofire Technologies is on a mission to give gun owners better tools for reducing preventable gun injuries and deaths, especially among children. We believe our technology, combined with a best-in-class customer experience, will define the future of firearms safety for the next generation. Our mission-driven approach has earned support from the firearm community, the tech world, and the media. Biofire employees are world-class engineers who have designed and tested firearms, medical devices, robots, cars, satellites, rockets, and supersonic jets. What unites our team is our commitment to safety and reliability that we bring to our work every day. Since CEO Kai Kloepfer founded Biofire in 2016, the company has won respect and accolades from gun owners and supporters who believe in technology’s potential to help reduce firearm accidents, criminal misuse, suicides and other tragic outcomes.
late stageDefense & Space
Pre-Seed Investor
Feb 2022
Biosensing.
Pre-Seed Investor
Dec 2021
Rollup is a mission-driven software company with the aim to help accelerate the development and optimization of complex hardware and systems.
Pre-Seed Investor
Sep 2021
The last mile energy company. We build solar energy charging stations and rent batteries in off-grid communities
Pre-Seed Investor
Jul 2021
(Re)creating dairy. Animal-free.™
Investor
2019
Structure and develop real eastate and other hard asset deals.
Investor
2019
Various board memberships
Experience · 14 entries
All (14)
Investments (12)
Founder (1)
Board (4)
2025
Board Observer
Feb 2025
Standard Nuclear
2024
Board Member
Oct 2024
The mission of Sampling Human is to couple health related decisions to their effects at the single cell level. It is inspired by the founders’ academic and professional efforts to extend what is measurable and to derive what must be measured. The human body is a complex system that cannot be quantified exhaustively or heuristically. Clinical diagnosis today is an imprecise art. On average, diagnosis of rare diseases is 5 years delayed with 50% of delays impacting the outcome. Misdiagnosis is far too common with a 66% likelihood of disagreement between experts. We are stuck with symptoms based medicine. The nature of physiological data is to blame. Decisions today are based on fuzzy variables (tired, drowsy, weak, tingling, itchy, etc). Better decisions will require precise knowledge regarding the fundamental physiological units of our bodies, CELLS.
Board Member
Jan 2024
We sequence proteins. Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. While DNA can reveal biological insights, proteins actually tell us what our bodies will do. We are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biology and disease.
2023
Board Observer
Mar 2023
We create novel optical/photonic components made uniquely possible by our 3D nano fabrication platform to create solutions for sensing, imaging, telecommunications, computation, and display.
Pre-Seed Investor
Jan 2023
Atomic Semi is building a small, fast semiconductor fab. We’ll build the tools ourselves then quickly push them to more advanced geometries. We’re building a small team of exceptional, hands-on engineers to make this happen.
Show all 14 entries ↓
Investment activity
2019–2025 · 12 investments
201922021320222202322024220251
Recent (last 2 years)Earlier